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ABSTRACT
Objective: To characterize paramagnetic MRI phase signal abnormalities in neuromyelitis optica
spectrum disorder (NMOSD) vs multiple sclerosis (MS) lesions in a cross-sectional study.
Methods: Ten patients with NMOSD and 10 patients with relapsing-remitting MS underwent
7-tesla brain MRI including supratentorial T2*-weighted imaging and supratentorial susceptibility
weighted imaging. Next, we analyzed intra- and perilesional paramagnetic phase changes on
susceptibility weighted imaging filtered magnetic resonance phase images.
Results:We frequently observedparamagnetic rim-like (75of232 lesions, 32%) or nodular (32of232
lesions, 14%) phase changes in MS lesions, but only rarely in NMOSD lesions (rim-like phase changes:
2 of 112 lesions, 2%, p , 0.001; nodular phase changes: 2 of 112 lesions, 2%, p , 0.001).
Conclusions: Rim-like or nodular paramagnetic MRI phase changes are characteristic for MS lesions
and not frequently detectable in NMOSD. Future prospective studies should ask whether these
imaging findings can be used as a biomarker to distinguish between NMOSD- and MS-related brain
lesions. Neurol Neuroimmunol Neuroinflamm 2016;3:e259; doi: 10.1212/NXI.0000000000000259
GLOSSARY
ICC 5 intraclass correlation; MS 5 multiple sclerosis; NMOSD 5 neuromyelitis optica spectrum disorder; SWI 5 suscepti-
bility weighted imaging; T2*w 5 T2*-weighted.
Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) are distinct
autoimmune CNS diseases with sometimes overlapping clinical phenotypes.1 Since treatment
options for these 2 CNS diseases differ considerably,1 the distinction between NMOSD andMS
is of high clinical relevance. Recently, new international consensus diagnostic criteria were
proposed for NMOSD emphasizing the role of MRI and aquaporin-4 immunoglobulin G
antibody testing.2 Notwithstanding this success, the distinction of NMOSD vs MS can still
be challenging in current clinical practice. Ultra-high field MRI at 7 tesla (T) has improved the
detection and morphologic characterization of brain lesions by visualizing a central intralesional
vein and a T2*-weighted (T2*w) hypointense rim around many MS lesions.3,4 Contrarily, these
imaging features are only rarely depictable in NMOSD lesions.3,4 At 3T, susceptibility-induced
MRI phase signal changes were reported to be specific for MS in contrast to other neurologic
disorders such as migraine, antiphospholipid syndrome, and Parkinson disease.5 Inspired by
these findings, we rescanned previously reported patients with NMOSD at 7T3 and included
additional NMOSD cases to describe MRI phase signal changes in NMOSD vs MS lesions in
a cross-sectional study.
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METHODS Study participants. Ten patients with NMOSD
underwent ultra-high field MRI at 7T. Inclusion criteria were
diagnosis of NMOSD as defined by the current international
consensus diagnostic criteria for NMOSD,2 age of at least
18 years, and no contraindications to 7T MRI. Four of these
patients have been previously reported in a 7T MRI study
on T2*w lesion morphology3 and were rescanned. Nine
patients with NMOSD were seropositive for aquaporin-4
immunoglobulin G. Ten patients with relapsing-remitting MS
as defined by the current panel criteria6 were selected from
a research database of the NeuroCure Clinical Research Center
as controls. More details are presented in table 1.
The study was approved by the local ethics committee (EA 1/
054/09). Written consent was obtained from all participants
before examination.
MRI acquisition. Ultra-high field MRIs were acquired using
a 7T Siemens whole body scanner (Magnetom; Siemens, Erlangen,
Germany) by applying a 24-channel receive head coil (Nova
Medical, Wilmington, MA) equipped with a birdcage volume
coil used for transmission. The imaging protocol included
supratentorial 2-dimensional T2*w fast low angle shot (echo
time 5 25.0 milliseconds [ms], repetition time 5 1,820 ms,
spatial resolution 5 0.5 3 0.5 3 2 mm3, supratentorial coverage,
number of slices 5 35) and supratentorial 3-dimensional gradient
echo flow-compensated susceptibility weighted imaging (SWI)
(echo time 5 14 ms, repetition time 5 25 ms, flip angle 5 12°,
spatial resolution 5 0.5 3 0.5 3 1.0 mm3) yielding magnitude,
SWI-filtered phase and reconstructed SWI images.
Image analysis. MRIs were analyzed by a trained investigator
(S.S.) blinded to clinical details (diagnosis, Expanded Disability
Status Scale score, age, sex) using the OsiriX software package
(version 3.8.1; OsiriX Foundation, Geneva, Switzerland). First,
all hyperintense brain lesions larger than 3 mm in diameter were
marked on T2*w images. The 3-mm cutoff was used to ensure an
optimal characterization of the lesion morphology. T2*w lesions
outside of the field of view of SWI-phase images were excluded
from further analyses.
Next, each existent T2*w lesion was marked on phase images
in a side-by-side analysis.
Hereby, the existence of phase changes in or around brain
lesions was noted and grouped into 4 categories: (1) lesions with
paramagnetic (positive) phase changes in the center of the lesions
that are nodular in appearance, (2) lesions with paramagnetic
(positive) phase changes at the edge of the lesions that are rim-
like in appearance, (3) lesions without any intralesional phase
changes, and (4) other lesions with intralesional phase changes
not meeting these criteria. The latter were termed “lesions with
unspecific phase changes” (figure). Since our scanner uses a left-
handed system, a paramagnetic (positive) phase shift corresponds
to a hyperintense or “bright” area on phase images. Phase changes
that were clearly related to a blood vessel were excluded.
In addition, a lesion with a central vessel within the inner
third of the lesion on axial T2*w images was classified as a peri-
vascular lesion by an expert reader regarding the 3-dimensional
shape of the lesion and the vessels.
Statistical analysis and interrater reliability. All analyses
were performed using IBM SPSS Statistics (version 20; IBM,
Armonk, NY). The p values ,0.05 were considered significant.
Because of the exploratory nature of the study, no adjustments
for multiple comparisons were made. Group differences in age,
disease duration, existence of a central vein, and intralesional phase
changes between NMOSD and MS were assessed using a nonpara-
metric Mann–Whitney U test. Pearson x2 was used to assess sex
differences, and Student t-test was used to investigate group differ-
ences in the Expanded Disability Status Scale. In addition, 10
randomly selected patients with MS or NMOSD were reanalyzed
by a second blinded investigator (K.M.) to assess interrater reliabil-
ity. For this reason, intraclass correlation (ICC) was calculated as
a 2-way mixed test of average measures using the consistencymodel.
RESULTS In total, we detected 112 brain lesions in
patients with NMOSD, and 232 brain lesions were
visualized in patients with MS on supratentorial
T2*w images.
Next, rim-like or nodular paramagnetic (positive) in-
tralesional phase changes were analyzed (figure). In MS,
32 of 232 lesions (14%) in 7 of 10 patients were char-
acterized by a nodular paramagnetic (positive) phase shift
and thus appeared “hyperintense” onmagnetic resonance
(MR) phase images corresponding to a hypointense sig-
nal on T2*w and/or SWIs (lesion category I; figure, A).
Furthermore, a distinct rim-like paramagnetic
(positive) phase shift was visible in 75 of 232 MS le-
sions (32%) in all but one patient with MS (lesion
category II; figure, B).
Contrarily, the vast majority of NMOSD lesions
were neither characterized by nodular (2 of 112 le-
sions, 2%, p, 0.001) nor rim-like intralesional phase
changes (2 of 112 lesions, 2%, p , 0.001; table 2).
Table 1 Demographic details
NMOSD RRMS
No. 10 10
Female, n 10 5a
Age, y, mean 6 SD 47 6 12 40 6 7b
Range 30–69 26–49
Disease duration,c y, mean 6 SD 8 6 7 6 6 4d
Range 1–29 0–12
EDSS score, median 3.75 1.5e
Range 1.5–6.0 0–2.5
NMOSD, n 10 NA
NMO 3 NA
ON 0 NA
LETM 7 NA
Abbreviations: EDSS 5 Expanded Disability Status
Scale; LETM 5 longitudinally extensive transverse myelitis;
NA 5 not applicable; NMO 5 neuromyelitis optica;
NMOSD 5 NMO spectrum disorder; ON 5 optic neuritis;
RRMS 5 relapsing remitting multiple sclerosis.
ap 5 0.010, Pearson x2 test to assess differences in sex
between patients with NMOSD and RRMS.
bp 5 0.043, Mann–Whitney U test to assess differences in
age between patients with NMOSD and RRMS.
cDisease duration 5 time since first symptoms.
dp 5 0.853, Mann–Whitney U test to assess differences in
disease duration between patients with NMOSD and
RRMS.
ep 5 0.001, Student t test to assess differences in the
EDSS between patients with NMOSD and RRMS.
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A significant proportion of lesions in patients with
NMOSD (107 of 112 lesions, 96%) or MS (116 of
232 lesions, 50%) did not show any MRI phase
changes (lesion category III; figure, C), and a total
number of 9 MS and 1 NMOSD lesions presented
with rather unspecific MRI phase changes (lesion cat-
egory IV; figure, D).
In addition, the existence of an intralesional cen-
tral vein was analyzed on T2*w images. As reported
previously,3,4 a central vein was typically visible in the
inner third of MS lesions (193 of 232 lesions, 83%)
but only rarely existent in NMOSD lesions (28 of
112 lesions, 25%, p , 0.001). The morphology of
NMOSD and MS lesions is detailed in table 2.
Interrater reliability. Interrater reliability was assessed
in a subgroup of 10 randomly selected patients. ICC
was .0.8 for lesion count (ICC5 0.90), the number
of lesions with a central vein (ICC 5 0.95), and the
number of lesions with rim-like (ICC 5 0.96) or
nodular (ICC 5 0.84) phase changes indicating
good interrater reliability of these parameters.
DISCUSSION In this study, we compared the mor-
phology of NMOSD vs MS lesions on high spatial
resolution SWI-filtered phase images and observed
distinct lesion characteristics that were nearly
exclusively found in MS but not in NMOSD
lesions. Thus, this work adds to the ongoing
discussion5 on the diagnostic value of phase white
matter signal abnormalities in differentiating MS
from other diseases.
In MS, the source of the phase contrast in or
around lesions remains speculative, but iron-rich
Figure Lesion morphology of NMOSD vs MS lesions
In this study, the existence of phase changes in or around brain lesions was noted and grouped into 4 categories. The figure shows examples of MS (A, B, D)
and NMOSD (C) lesions imaged using T2*w and phase MRI. In the bottom row, a schematic is presented for each type of lesion illustrating ideal theoretic
phase image appearance. Briefly, category I lesions (A) are characterized by paramagnetic (positive) phase changes in the center of the lesions that are
nodular in appearance. Category II lesions (B) show paramagnetic (positive) phase changes at the edge of the lesions that are rim-like in appearance, and
category III lesions (C) do not exhibit any intralesional phase changes. Finally, lesions with intralesional phase changes not meeting these criteria are category
IV lesions (D). In this example (D), the MS lesion appears to have a small T2*w hypointense rim, but the corresponding phase changes are inconclusive and
were thus categorized into lesion category IV. In addition, note the existence of a central vein in the center of the MS lesions (A, B, D) and the absence of such
a vessel in the neuromyelitis optica lesion (C). MS 5 multiple sclerosis; NMOSD 5 neuromyelitis optica spectrum disorder; T2*w 5 T2*-weighted.
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macrophages or microglia,7 solutes, proteins, antibod-
ies, cytokines, and immune cells have been hypothe-
sized to cause rim-like phase changes around MS
lesions.8
Nodular phase changes—a feature of another pro-
portion of MS lesions as reported previously9—were
discussed to be caused by iron deposits as a conse-
quence of, e.g., dying iron-rich oligodendrocytes,10
perivascular hemoglobin leakage,11 or a loss of dia-
magnetic myelin.12
In NMOSD, such nodular or rim-like paramag-
netic phase changes were virtually absent. These dif-
ferences may represent variant patterns of lesion
evolution or iron metabolism between MS and
NMOSD.13 In MS, evidence has emerged that brain
iron metabolism is altered since iron accumulates, e.g.,
in the basal ganglia.14 In alignment with a previous
study that failed to identify abnormal iron deposits
in the basal ganglia of patients with NMOSD,15 our
data suggest that NMOSD is not associated with alter-
ation in brain iron metabolism, but histopathologic
confirmation is needed.
Some limitations of this study of a small sample
size need to be addressed. The NMOSD group was
older than the MS group, which may have influenced
our results since the magnetic susceptibility of (MS)
brain lesions decreases with aging of the lesion.16
Most important, lesions within the brainstem, spinal
cord, and optic nerves could not be analyzed, and
brain lesions typical for NMOSD17 were not present
in our NMOSD cohort. Thus, the existence of
any MRI phase changes in these lesions remains
unknown. From a technical point of view, signal
inhomogeneities were present on 7T T2*w images,
and automated procedures to determine the total
lesion volume were thus not performed. Finally, we
cannot exclude that differences in lesion count or
volume between the subgroups may have influenced
our results.
In conclusion, paramagnetic intralesional phase
changes were virtually absent in NMOSD but fre-
quently detectable in MS. Future work should
address the question of whether these imaging find-
ings in or around lesions can indeed be used as a bio-
marker to better distinguish MS from NMOSD.
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